Exbio — Research products — Antibodies — CD and related antigens — Anti-DR3 Purified

Anti-DR3 Purified

Regulatory status

RUO

Antigen

DR3

Clone

JD3

Format

Purified

Reactivity

Human

Application

FC (QC tested)

Variant

0.1 mg

11-757-C100

In stock

143.00 USD

0.025 mg

11-757-C025

Delivery 1 week

71.50 USD

Variant

0.1 mg

11-757-C100

In stock

143.00 USD

0.025 mg

11-757-C025

Delivery 1 week

71.50 USD

Contact distributor

Product details

Description

References

SDS download

Isotype

Mouse IgG1

Specificity

The mouse monoclonal antibody JD3 recognizes an extracellular epitope of DR3 (APO-3, TNFRSF25), a transmembrane protein of TNFR superfamily expressed mainly in lymphocyte-enriched tissues.

Application

FC (QC tested)

Application details

Flow cytometry: Recommended dilution: 1-4 μg/ml.

Reactivity

Human

Immunogen

human DR3-Ig fusion protein

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

TNFRSF25, TR3, DDR3, LARD, APO-3, TRAMP, WSL-1, WSL-LR, TNFRSF12

Antigen description

DR3, also known as APO-3, TRAMP or TNFRSF25, is a death domain-containing receptor of TNFR family, which is expressed preferentially in peripheral blood leukocytes and in the lymphocyte-enriched tissues. Its expression has been shown to be especially up-regulated in activated T cells. DR3 participates e.g. in the removal of self-reactive T cells in the thymus. The ligand for DR3 is TL1A (TNF-like ligand 1A), which is expressed in a variety of cell types (induced by inflammatory stimuli), and can also be released as a soluble factor. The TL1A/DR3 axis has been shown to costimulate T cells to produce a wide variety of cytokines and leads to T cell differentiation towards Th1 and Th17 types.

Entrez Gene ID 8718

UniProt ID Q93038

Product specific references:

Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K, Yagita H: Multiple pathways of TWEAK-induced cell death. J Immunol. 2002 Jan 15;168(2):734-43.
PubMed

Cavallini C, Lovato O, Bertolaso A, Pacelli L, Zoratti E, Zanolin E, Krampera M, Zamò A, Tecchio C, Cassatella MA, Pizzolo G, Scupoli MT: The TNF-family cytokine TL1A inhibits proliferation of human activated B cells. PLoS One. 2013;8(4):e60136.
PubMed

Jones GW, Stumhofer JS, Foster T, Twohig JP, Hertzog P, Topley N, Williams AS, Hunter CA, Jenkins BJ, Wang EC, Jones SA: Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J. 2011 Jan;25(1):409-19.
PubMed

Yi B, Zhang M, Schwartz-Albiez R, Cao Y: Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells. Int J Oncol. 2011 Jun;38(6):1565-73.
PubMed